Healthy Clinical Trial
— ADAPOfficial title:
Device Quantification of Scratch and Sleep in Atopic Dermatitis With Accelerometry and Polysomnography (ADAP) Study
NCT number | NCT05583019 |
Other study ID # | SSG0001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 27, 2022 |
Est. completion date | May 11, 2023 |
Verified date | August 2023 |
Source | SymmetryScience Group, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this research is to better understand how wrist-worn study devices that measure activity/motion ('accelerometry devices') can be used to assess scratching and sleep in participants aged 12-75 years, with and without Atopic Dermatitis (AD, eczema), in both a sleep laboratory (hotel) setting and in a daily life/home setting. In this study, we will be using three different wrist devices to collect information: an Apple Watch Series 7, an Actigraph CentrePoint Insights Watch (CPIW) and a GENEActiv Original Watch. We will also compare the movement and sleep measurements recorded on the devices to thermal video and sleep assessments done in the sleep laboratory (hotel) as well as compare them to Patient Reported Outcome (PRO) assessments.
Status | Completed |
Enrollment | 88 |
Est. completion date | May 11, 2023 |
Est. primary completion date | May 11, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 75 Years |
Eligibility | Inclusion Criteria: Atopic Dermatitis (AD) Participants: 1. Participants aged =12 years of age and <75 years of age at Day 1. 2. Written informed consent from participant or parent(s)/guardian(s) and assent from the participant (where assent is applicable). 3. Participant (and parent(s)/guardian(s)) are willing and able to comply with study instructions, study visits, and procedures. 4. Native English speakers or demonstrated fluency in English (participant; and parent(s)/guardian(s) as needed) 5. Have a clinical diagnosis of AD according to the criteria of Hanifin and Rajka (concomitant AD treatments are permitted on study). 6. Have AD involvement = 5% Treatable % Body Surface Area (BSA) excluding the scalp. 7. Have an Investigator's Static Global Assessment (ISGA) score of Mild (2), Moderate (3) or Severe (4) at the screening visit within 14 days of study enrollment. 8. Have a minimum Peak Pruritus Numerical Rating Scale (PP-NRS) assessment score of 3 (out of 10). 9. Wide Range Achievement Test-4 (WRAT-4) Word Reading Subtest equivalent to 8th grade reading level or greater (for ages =18 years only). Healthy (non-AD) Participants: 1. Participants aged =12 years of age and <75 years of age at Day 1. 2. Written informed consent from participant or parent(s)/guardian(s) and assent from the participant (where assent is applicable). 3. Participant (and parent(s)/guardian(s)) are willing and able to comply with study instructions, study visits, and procedures. 4. Native English speakers or demonstrated fluency in English (participant; and parent(s)/guardian(s) as needed) 5. Does not have suspected or confirmed clinical diagnosis of AD (according to the criteria of Hanifin and Rajka). 6. Have an ISGA score of Clear (0) or Almost Clear (1) at the screening visit within 14 days of study enrollment. 7. WRAT-4 Word Reading Subtest equivalent to 8th grade reading level or greater (for ages =18 years only). Exclusion Criteria: Atopic Dermatitis (AD) Participants: 1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent non-AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome) or clinically significant finding at screening that precludes participant's participation in study activities. 2. Allergy to polyurethane resin (strap/wristband component). 3. Has documented non-AD related insomnia, sleep apnea or other sleep-related disorders (e.g., narcolepsy, restless legs syndrome, circadian rhythm disorder). 4. AD affected surface areas are in a location of device placement. 5. If participant has a history of angioedema or anaphylaxis and has had any anaphylactic reactions within the past 6 months. 6. Has unstable AD (Total BSA>40%). 7. Has a significant active systemic or localized infection, including actively infected AD. 8. Has recently (within 30 days of Day 1) participated in or is currently involved in another drug or device research study for AD. 9. Has any planned surgical or medical procedure that would overlap with study participation. 10. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study. 11. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 6 months of baseline as disclosed by participant during evaluation (for those participants over the age of 21). 12. Is a female who is breastfeeding or pregnant, as disclosed by the participant. 13. Current shift worker or travel across more than two time zones in the past 2 weeks, and/or during the study period. 14. Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices. Healthy (non-AD) Participants: 1. Has any clinically significant medical disorder, condition, disease (including any active/potentially recurrent dermatological conditions (such as Netherton syndrome) or clinically significant finding at screening that precludes participant's participation in study activities. 2. Allergy to polyurethane resin (strap/wristband component). 3. Has documented clinically diagnosed insomnia, sleep apnea or other sleep-related disorders (e.g., narcolepsy, restless legs syndrome, circadian rhythm disorder). 4. If participant has a history of angioedema or anaphylaxis and has had any anaphylactic reactions within the past 6 months. 5. Has recently (within 30 days of Day 1) participated in or is currently involved in another drug or device research study. 6. Has any planned surgical or medical procedure that would overlap with study participation. 7. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study. 8. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 6 months of baseline as disclosed by participant during evaluation (for those participants over the age of 21). 9. Is a female who is breastfeeding or pregnant, as disclosed by the participant. 10. Current shift worker or travel across more than two time zones in the past 2 weeks, and/or during the study period. 11. Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices. |
Country | Name | City | State |
---|---|---|---|
United States | Hampton Inn & Suites | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
SymmetryScience Group, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantification of scratch using GENEActiv watches to assess triaxial accelerometry | One GENEActiv watch will be used on each wrist at a sampling rate of 100 Hz to measure movement in the x, y, and z direction. | 14 days +/- 2 days | |
Primary | Quantification of scratch using Centrepoint Insights Watches (CPIW) to assess triaxial accelerometry | One CPIW watch will be used on each wrist at a sampling rate of 128 Hz to measure movement in the x, y, and z direction. | 14 days +/- 2 days | |
Primary | Quantification of scratch using Apple Watches to assess triaxial accelerometry | One Apple Watch will be used on each wrist at a sampling rate of 100 Hz to measure movement in the x, y, and z direction. | 14 days +/- 2 days | |
Primary | Quantification of sleep occurrences using polysomnography | Polysomnography (PSG) will be used to report the number of sleep occurrences based on the scoring guide provided by the American Academy of Sleep Medicine (AASM). | 1 night | |
Primary | Sleep stage scoring using polysomnography | Polysomnography (PSG) will be used to report the appropriate sleep staging based on the scoring guide provided by the American Academy of Sleep Medicine (AASM). The following sleep stages will be scored: Stage W (wakefulness), Stage N1 (NREM 1), Stage N2 (NREM 2), Stage N3 (NREM 3), Stage N (NREM), and Stage R (REM). | 1 night |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |